Page 40 - Confidence Interval News Today

This study aimed to understand the factors associated with consistent condom use among OS-YP aged 15-24 years old on ART in Central Uganda.

Could cardiovascular health be key in preventing the onset of depression in the elderly? Learn more in this new PLOS ONE study.

1. Widespread underlying SARS-CoV-2 seropositivity was observed in Gauteng province, South Africa, before the omicron wave. 2. Epidemiologic data demonstrated a decoupling of hospitalizations and deaths from infections while omicron was circulating. Evidence Rating Level: 2 (Good) Study Rundown: The Omicron variant was first identified in November 2021 in Gauteng province, South Africa, and was […]

1. Based on the study, there is a small absolute risk for shoulder conditions after vaccination. 2. Simultaneous administration of vaccines was associated with a higher risk for shoulder conditions among the elderly. Evidence Rating Level: 2 (Good) Study Rundown: There have been previous reports of shoulder injuries related to vaccine administration, such as deltoid […]

PALM BEACH, Fla., April 13, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities

Neoadjuvant Opdivo (nivolumab) with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial

Approval based on Phase 3 CheckMate -274 trial results showing that adjuvant treatment with Opdivo significantly reduced patients' risk of disease recurrence or death compared to placebo Opdivo

Opdivo with chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival compared to chemotherapy alone in this patient population; approval based on

Approval based on Phase 3 CheckMate -274 trial results showing that adjuvant treatment with Opdivo significantly reduced patients’ risk of disease recurrence or death compared to placeboOpdivo is now the first and only adjuvant immunotherapy option approved in this setting in the European UnionDecision marks the thi...

Approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer1In the Phase 3 CheckMate -816 trial, Opdivo plus platinum-doublet chemotherapy significantly improved event-free survival and pathologic complete response compared to platinum-doublet chemotherapy al...